[英文研究]比较使用克拉夫定和恩替卡韦,用于初治慢性乙型

StephenW

J Clin Gastroenterol. 2011 May 25. [Epub ahead of print]

Comparison of Clevudine and Entecavir for Treatment-naive Patients With
Chronic Hepatitis B Virus Infection: Two Year Follow-up Data.


比较
使用克拉夫定和恩替卡韦,用于
初治
慢性乙型肝炎病毒感染
患者：两个年随访资料。

Yoon EL, Yim HJ, Lee HJ, Lee YS, Kim JH, Jung ES, Kim JH, Seo YS, Yeon JE,
Lee HS, Um SH, Byun KS.

Source
Division of Gastroenterology and Hepatology, Department of Internal
Medicine, Korea University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIM:
Clevudine and entecavir are highly potent antiviral agents being used in
treatment of chronic hepatitis B. However, no data comparing clinical
efficacy and safety of these 2 drugs over a long-term period is available.
The aims of this study are to compare virologic, biochemical, and serologic
response rates of clevudine and entecavir, as well as treatment failure
rates up to 2 years.

METHODS:
Data of patients who started clevudine (n=86) or entecavir (n=159) as a
primary treatment for chronic hepatitis B at Korea University Ansan or Guro
Hospital between January 2007 and June 2008 were analyzed.

RESULTS:
Treatment responses were compared at 3-month intervals up to 24 months. Per
protocol analysis showed no difference in virologic responses between the 2
groups at all time points, except at 18 months. When analyzed on
intention-to-treat basis for virologic response at 24 months, the response
rates were 45.3% in the clevudine group and 72.3% in the entecavir group,
which are significantly different (P<0.001). Rates of biochemical response
and HBeAg seroconversion were not significantly different between the
groups at all time points. Up to 24 months, antiviral resistance developed
in 18 patients (24.4%) in the clevudine group. Clevudine was discontinued
owing to muscle-related problems in 10 patients (11.6%).

CONCLUSIONS:
Although both drugs showed potent antiviral activity, entecavir showed
better virologic response at 24 months, primarily owing to treatment
failures in the clevudine group that were associated with development of
drug resistance and muscle-related problems.

PMID: 21617542 [PubMed - as supplied by publisher]



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

J Clin消化。 2011年5月25日。
克拉夫定和恩替卡韦的比较 未接受治疗过的慢性乙型肝炎病毒感染病人：两个年随访资料。

尹EL，任某HJ，HJ李，李渝生，金JH，荣ES，金津海，徐渝生，妍乙脑，
李协，庵SH，卞KS。

来源
胃肠病学和肝病科，内部部
医药，高丽大学医学院，韩国汉城。

摘要

背景/目的：
克拉夫定和恩替卡韦正在使用强效抗病毒药物
慢性乙型肝炎的治疗，但没有临床数据比较
疗效和较长远的时期这两个药物的安全性是可用的。
这项研究的目的是比较病毒学，生化和血清学
响应率克拉夫定和恩替卡韦，以及治疗失败
长达2年的利率。

方法：
数据谁的病人开始作为一个克拉夫定（N = 86）或恩替卡韦（N = 159）
主要治疗慢性乙型肝炎在高丽大学安山或九老区
2007年1月至2008年6月医院进行了分析。

结果：
治疗反应比在3个月的时间长达24个月。每个
协议分析显示，没有病毒学反应之间的差异2
在各时间点组，除了在18个月。当分析了
意向性治疗24个月的病毒学反应的基础上，反应
率分别为45.3％，在克拉夫定组和恩替卡韦组的72.3％，
这些显着差异（P <0.001）。房价的生化反应
和HBeAg血清转换之间无显着不同
组各时间点。长达24个月，病毒抗药性发展
在18例（24.4％）在克拉夫定组。克拉夫定被中断
由于肌肉有关的10例（11.6％）的问题。

结论：
虽然这两种药物表现出强大的抗病毒活性，结果显示恩替卡韦
更好地在24个月，主要是由于在克拉夫定组,病毒学应答处理与发展相关的故障
耐药性和肌肉有关的问题。

无敌抗体

可乐的重大利好消息，就这样？

StephenW

无敌抗体 发表于 2011-6-18 18:59
可乐的重大利好消息，就这样？

不知道. 临床试验是在韩国举行.

interdetect

回复 StephenW 的帖子

very good，必须正视它的副作用。

无敌抗体

还非常好？我看有点失望吧.